We recently compiled a list of the These 10 Firms Were Last Week's Worst Performers. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other stocks.

Wall Street’s main indices finished firmer on Friday, with all main indices settling in the green territory ahead of President-elect Donald Trump’s return to the White House.

Week-on-week, the Dow eked out a 3.81-percent gain, the S&P rallied 3.79 percent, while the Nasdaq increased by 3.84 percent.

Ten companies from diverse sectors, however, ended Friday weaker, posting notable declines versus the week prior. In this article, let’s look at which firms suffered a bloodbath and the reasons that dragged their performance.

For this week’s list, we only focused on companies with a market capitalization of at least $2 billion and a minimum trading volume of $5 million.

A scientist surrounded by vials and beakers in a modern laboratory, proudly displaying a vaccine.

Moderna, Inc. (NASDAQ:MRNA)

Shares of Moderna, Inc. (NASDAQ:MRNA) nosedived by 19 percent week-on-week to finish Friday’s trading at $34.06 versus the $42.25 close a week prior after projecting a steep decline in its 2025 revenues to between $1.5 billion to $2.5 billion as compared with $3.1 billion in 2024 and $19 billion at the peak of the Covid-19 pandemic.

The lower earnings projection came on the heels of lower vaccine demand for COVID-19 vaccines and slow adoption of its respiratory syncytial virus (RSV) shot, forcing Moderna to cut costs.

Moderna (NASDAQ:MRNA) CEO Stéphane Bancel said that the vaccine maker aims to reduce 2025 cash costs by $1 billion with a plan for an additional $500 million in 2026. It expects to end 2025 with cash and investments of about $6 billion.

The company is also betting on new products to help accelerate growth. It has filed an application with the US FDA for the approval of its combination vaccine to protect against COVID-19 and influenza.

Overall MRNA ranks 2nd on our list of last week's worst performers. While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MRNA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

 

Disclosure: None. This article is originally published at Insider Monkey.